The ICH E9(R1) Estimand Framework in the Context of Real-World Data and Observational Studies

被引：0
|
作者：
Husemoen, Lotte [1 ]
Morga, Antonia [2 ]
Remiro-Azocar, Antonio [3 ]
Kleinjung, Frank [4 ]
Rantell, Khadija Rerhou [5 ]
Besseghir, Amel [6 ]
Rosettani, Barbara [7 ]
Allignol, Arthur [8 ]
Vaitsiakhovich, Tatsiana [9 ]
Polavieja, Pepa [1 ]
机构：
[1] Novo Nordisk, Bagsvaerd, Denmark
[2] Astellas Pharma Europe Ltd, Addlestone, Surrey, England
[3] Bayer, Leverkusen, Germany
[4] Bayer AG, Leverkusen, Germany
[5] MHRA, London, England
[6] SwissBiosim, Biosimilars, Biopharmaceut, Eysins, Switzerland
[7] Bristol Myers Squibb, New York, NY USA
[8] Daiichi Sankyo Europe GmbH, Munich, Germany
[9] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1229
引用
收藏
页码：553 / 554
页数：2
相关论文
共 50 条
  • [1] Application of estimand framework in ICH E9 (R1) to vaccine trials
    Fu, Rong
    Li, Hal
    Wang, Xuelong
    Shou, Qiong
    Wang, William W. B.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (04) : 502 - 513
  • [2] Application of estimand framework in ICH E9 (R1) to safety evaluation
    Wang, Xuelong
    Yang, Ping
    Yuan, Shuai S.
    Wang, William W. B.
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2023, 33 (04) : 476 - 487
  • [3] Clinical and Statistical Perspectives on the ICH E9(R1) Estimand Framework Implementation
    Ionan, Alexei C.
    Paterniti, Miya
    Mehrotra, Devan, V
    Scott, John
    Ratitch, Bohdana
    Collins, Sylva
    Gomatam, Shanti
    Nie, Lei
    Rufibach, Kaspar
    Bretz, Frank
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2023, 15 (03): : 554 - 559
  • [4] Estimands in observational studies: Some considerations beyond ICH E9 (R1)
    Li, Heng
    Wang, Chenguang
    Chen, Wei-Chen
    Lu, Nelson
    Song, Changhong
    Tiwari, Ram
    Xu, Yunling
    Yue, Lilly Q.
    PHARMACEUTICAL STATISTICS, 2022, 21 (05) : 835 - 844
  • [5] The estimands framework: a primer on the ICH E9(R1) addendum
    Kahan, Brennan C.
    Hindley, Joanna
    Edwards, Mark
    Cro, Suzie
    Morris, Tim P.
    BMJ-BRITISH MEDICAL JOURNAL, 2024, 384
  • [6] Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice
    Bohdana Ratitch
    James Bell
    Craig Mallinckrodt
    Jonathan W. Bartlett
    Niti Goel
    Geert Molenberghs
    Michael O’Kelly
    Pritibha Singh
    Ilya Lipkovich
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 324 - 341
  • [7] Choosing Estimands in Clinical Trials: Putting the ICH E9(R1) Into Practice
    Ratitch, Bohdana
    Bell, James
    Mallinckrodt, Craig
    Bartlett, Jonathan W.
    Goel, Niti
    Molenberghs, Geert
    O'Kelly, Michael
    Singh, Pritibha
    Lipkovich, Ilya
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 324 - 341
  • [8] Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework
    Mitroiu, Marian
    Teerenstra, Steven
    Rengerink, Katrien Oude
    Petavy, Frank
    Roes, Kit C. B.
    PHARMACEUTICAL STATISTICS, 2022, 21 (05) : 1037 - 1057
  • [9] Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice
    Mallinckrodt, C. H.
    Bell, J.
    Liu, G.
    Ratitch, B.
    O'Kelly, M.
    Lipkovich, I
    Singh, P.
    Xu, L.
    Molenberghs, G.
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (02) : 353 - 364
  • [10] Aligning Estimators With Estimands in Clinical Trials: Putting the ICH E9(R1) Guidelines Into Practice
    C. H. Mallinckrodt
    J. Bell
    G. Liu
    B. Ratitch
    M. O’Kelly
    I. Lipkovich
    P. Singh
    L. Xu
    G. Molenberghs
    Therapeutic Innovation & Regulatory Science, 2020, 54 : 353 - 364
12345